Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo

Fumiaki Tanaka, Hiroshi Yamaguchi, Mitsuhiko Ohta, Kohjiro Mashino, Hideto Sonoda, Noriaki Sadanaga, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) after low-dose chemotherapy using cisplatin + 5-FU. Combination of i.t. injection of DC and systemic chemotherapy induced complete rejection of the treated tumor, MC38 murine adenocarcinoma. Furthermore, the antitumor effects were also observed on a distant tumor inoculated in the contralateral flank of the animal. When 10x the number of tumor cells were inoculated, the antitumor effect of the combination of DC after chemotherapy was also confirmed and in comparison to that of DC or chemotherapy alone, thereafter contributed to a greater prolongation of survival. To analyze the mechanisms of the systemic antitumor effect generated in this system, we assessed the cytolytic activity against inoculated tumors. The cytolytic activity of effector cells from treated animals was shown to be tumor-specific and was mainly CD8 and MHC Class-I (p < 0.0 1) restricted. CD4 and MHC Class-II treatment marginally inhibited the cytolytic activity but not significantly (p = 0.07, 0.08 respectively). The cytolysis of effector cells was enhanced more significantly by the treatment of both DC and chemotherapy, than that of either DC or chemotherapy alone. Our study suggests that the strategy of i.t. injection of DC after low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the clinical settings.

Original languageEnglish
Pages (from-to)265-269
Number of pages5
JournalInternational Journal of Cancer
Volume101
Issue number3
DOIs
Publication statusPublished - Sep 20 2002

Fingerprint

Dendritic Cells
Drug Therapy
Injections
Pharmaceutical Preparations
Neoplasms
Therapeutics
Weapons
Fluorouracil
Cisplatin
Adenocarcinoma
Cell Count
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. / Tanaka, Fumiaki; Yamaguchi, Hiroshi; Ohta, Mitsuhiko; Mashino, Kohjiro; Sonoda, Hideto; Sadanaga, Noriaki; Inoue, Hiroshi; Mori, Masaki.

In: International Journal of Cancer, Vol. 101, No. 3, 20.09.2002, p. 265-269.

Research output: Contribution to journalArticle

Tanaka, Fumiaki ; Yamaguchi, Hiroshi ; Ohta, Mitsuhiko ; Mashino, Kohjiro ; Sonoda, Hideto ; Sadanaga, Noriaki ; Inoue, Hiroshi ; Mori, Masaki. / Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. In: International Journal of Cancer. 2002 ; Vol. 101, No. 3. pp. 265-269.
@article{06f3e87150ac48548af8498fde2f0fd8,
title = "Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo",
abstract = "We investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) after low-dose chemotherapy using cisplatin + 5-FU. Combination of i.t. injection of DC and systemic chemotherapy induced complete rejection of the treated tumor, MC38 murine adenocarcinoma. Furthermore, the antitumor effects were also observed on a distant tumor inoculated in the contralateral flank of the animal. When 10x the number of tumor cells were inoculated, the antitumor effect of the combination of DC after chemotherapy was also confirmed and in comparison to that of DC or chemotherapy alone, thereafter contributed to a greater prolongation of survival. To analyze the mechanisms of the systemic antitumor effect generated in this system, we assessed the cytolytic activity against inoculated tumors. The cytolytic activity of effector cells from treated animals was shown to be tumor-specific and was mainly CD8 and MHC Class-I (p < 0.0 1) restricted. CD4 and MHC Class-II treatment marginally inhibited the cytolytic activity but not significantly (p = 0.07, 0.08 respectively). The cytolysis of effector cells was enhanced more significantly by the treatment of both DC and chemotherapy, than that of either DC or chemotherapy alone. Our study suggests that the strategy of i.t. injection of DC after low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the clinical settings.",
author = "Fumiaki Tanaka and Hiroshi Yamaguchi and Mitsuhiko Ohta and Kohjiro Mashino and Hideto Sonoda and Noriaki Sadanaga and Hiroshi Inoue and Masaki Mori",
year = "2002",
month = "9",
day = "20",
doi = "10.1002/ijc.10597",
language = "English",
volume = "101",
pages = "265--269",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo

AU - Tanaka, Fumiaki

AU - Yamaguchi, Hiroshi

AU - Ohta, Mitsuhiko

AU - Mashino, Kohjiro

AU - Sonoda, Hideto

AU - Sadanaga, Noriaki

AU - Inoue, Hiroshi

AU - Mori, Masaki

PY - 2002/9/20

Y1 - 2002/9/20

N2 - We investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) after low-dose chemotherapy using cisplatin + 5-FU. Combination of i.t. injection of DC and systemic chemotherapy induced complete rejection of the treated tumor, MC38 murine adenocarcinoma. Furthermore, the antitumor effects were also observed on a distant tumor inoculated in the contralateral flank of the animal. When 10x the number of tumor cells were inoculated, the antitumor effect of the combination of DC after chemotherapy was also confirmed and in comparison to that of DC or chemotherapy alone, thereafter contributed to a greater prolongation of survival. To analyze the mechanisms of the systemic antitumor effect generated in this system, we assessed the cytolytic activity against inoculated tumors. The cytolytic activity of effector cells from treated animals was shown to be tumor-specific and was mainly CD8 and MHC Class-I (p < 0.0 1) restricted. CD4 and MHC Class-II treatment marginally inhibited the cytolytic activity but not significantly (p = 0.07, 0.08 respectively). The cytolysis of effector cells was enhanced more significantly by the treatment of both DC and chemotherapy, than that of either DC or chemotherapy alone. Our study suggests that the strategy of i.t. injection of DC after low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the clinical settings.

AB - We investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) after low-dose chemotherapy using cisplatin + 5-FU. Combination of i.t. injection of DC and systemic chemotherapy induced complete rejection of the treated tumor, MC38 murine adenocarcinoma. Furthermore, the antitumor effects were also observed on a distant tumor inoculated in the contralateral flank of the animal. When 10x the number of tumor cells were inoculated, the antitumor effect of the combination of DC after chemotherapy was also confirmed and in comparison to that of DC or chemotherapy alone, thereafter contributed to a greater prolongation of survival. To analyze the mechanisms of the systemic antitumor effect generated in this system, we assessed the cytolytic activity against inoculated tumors. The cytolytic activity of effector cells from treated animals was shown to be tumor-specific and was mainly CD8 and MHC Class-I (p < 0.0 1) restricted. CD4 and MHC Class-II treatment marginally inhibited the cytolytic activity but not significantly (p = 0.07, 0.08 respectively). The cytolysis of effector cells was enhanced more significantly by the treatment of both DC and chemotherapy, than that of either DC or chemotherapy alone. Our study suggests that the strategy of i.t. injection of DC after low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=0037144352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037144352&partnerID=8YFLogxK

U2 - 10.1002/ijc.10597

DO - 10.1002/ijc.10597

M3 - Article

C2 - 12209978

AN - SCOPUS:0037144352

VL - 101

SP - 265

EP - 269

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -